Evidence map›Paper›PMID 38622150›Full record

Trial reportTranslational psychiatry2024

LSD increases sleep duration the night after microdosing.

Nathan Allen, Aron Jeremiah, Robin Murphy, Rachael Sumner, Anna Forsyth, Nicholas Hoeh, David B Menkes, William Evans, Suresh Muthukumaraswamy, Frederick Sundram and 1 more

Registry-linked trialOpen access · goldAbstract readRandomized Controlled TrialClinical Trial, Phase I
In one paragraph

Trial report in Translational psychiatry, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07017478 (Mood Effects of Serotonin Agonists), which is not on this map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
8.3field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07017478 early_phase1completednot on this mapstarted 2025, after this paper: background citation

Mood Effects of Serotonin Agonists: Depression

TypeinterventionalSponsorUniversity of ChicagoRan2025 to 2026Enrolled41ConditionsLSD, Major Depressive Disorder, DepressionArmsLSD, Placebo
3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it, 13 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Addressing blinding in classic psychedelic studies with innovative active placebos.The international journal of neuropsychopharmacology · 2025
    Review
  6. Review
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 1 institution in 1 country.

Nathan Allen *Faculty of Engineering, University of Auckland, Auckland, 1010, New Zealand. nathan.allen@auckland.ac.nz.ORCID 0000-0001-7876-819X
Aron Jeremiah *Faculty of Engineering, University of Auckland, Auckland, 1010, New Zealand.
Robin MurphySchool of Pharmacy, Faculty of Medical and Health Sciences, University of Auckland, 85 Park Road, Grafton, Auckland, 1023, New Zealand.
Rachael SumnerSchool of Pharmacy, Faculty of Medical and Health Sciences, University of Auckland, 85 Park Road, Grafton, Auckland, 1023, New Zealand.ORCID 0000-0002-2652-4617
Anna ForsythSchool of Pharmacy, Faculty of Medical and Health Sciences, University of Auckland, 85 Park Road, Grafton, Auckland, 1023, New Zealand.
Nicholas HoehDepartment of Psychological Medicine, Faculty of Medical and Health Sciences, University of Auckland, 85 Park Road, Auckland, 1023, New Zealand.ORCID 0000-0002-8013-1208
David B MenkesDepartment of Psychological Medicine, Faculty of Medical and Health Sciences, University of Auckland, 85 Park Road, Auckland, 1023, New Zealand.ORCID 0000-0003-3760-7896
William EvansMana Health, 7 Ruskin St, Parnell, Auckland, 1052, New Zealand.
Suresh MuthukumaraswamySchool of Pharmacy, Faculty of Medical and Health Sciences, University of Auckland, 85 Park Road, Grafton, Auckland, 1023, New Zealand.ORCID 0000-0001-7042-3920
Frederick SundramDepartment of Psychological Medicine, Faculty of Medical and Health Sciences, University of Auckland, 85 Park Road, Auckland, 1023, New Zealand.ORCID 0000-0002-6311-9856
Partha RoopFaculty of Engineering, University of Auckland, Auckland, 1010, New Zealand.
University of Auckland · NZ

Funding

Manatu Hauora | Health Research Council of New Zealand (HRC) 20/845
6 · The paper itself

Abstract

Microdosing psychedelic drugs at a level below the threshold to induce hallucinations is an increasingly common lifestyle practice. However, the effects of microdosing on sleep have not been previously reported. Here, we report results from a Phase 1 randomized controlled trial in which 80 healthy adult male volunteers received a 6-week course of either LSD (10 µg) or placebo with doses self-administered every third day. Participants used a commercially available sleep/activity tracker for the duration of the trial. Data from 3231 nights of sleep showed that on the night after microdosing, participants in the LSD group slept an extra 24.3 min per night (95% Confidence Interval 10.3-38.3 min) compared to placebo-with no reductions of sleep observed on the dosing day itself. There were no changes in the proportion of time spent in various sleep stages or in participant physical activity. These results show a clear modification of the physiological sleep requirements in healthy male volunteers who microdose LSD. The clear, clinically significant changes in objective measurements of sleep observed are difficult to explain as a placebo effect. Trial registration: Australian New Zealand Clinical Trials Registry: A randomized, double-blind, placebo-controlled trial of repeated microdoses of lysergic acid diethylamide (LSD) in healthy volunteers; https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=381476 ; ACTRN12621000436875.

Indexed as

HallucinogensSleep DurationAdultAustraliaDouble-Blind MethodHealthy VolunteersHumansMaleSleepHallucinogens

Identifiers

PMID38622150
PMCPMC11018829
OpenAlexW4394808303

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.